Hepatic ischemia reperfusion injury: Contemporary perspectives on pathogenic mechanisms and basis for hepatoprotection-the good, bad and deadly

Journal of Gastroenterology and Hepatology (Australia)

Volumn 26, Issue SUPPL. 1, 2011, Pages 180-187

  Teoh, Narci C ^a  

^a The Australian National University   (Australia)

Author keywords

Chemokines; Heme oxygenase; Hepatocyte cell death; Inflammation; Kupffer cells; Liver ischemia reperfusion injury; Neutrophils; Receptor for Advanced Glycation End Products (RAGE); Toll Like Receptor (TLR); Tumor necrosis factor

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; CXCL1 CHEMOKINE; CXCL2 CHEMOKINE; CXCL3 CHEMOKINE; FERRITIN; HEME OXYGENASE; INTERLEUKIN 12; REACTIVE OXYGEN METABOLITE; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 10; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; HEPATIC ISCHEMIA REPERFUSION INJURY; HUMAN; LIVER ISCHEMIA; LIVER PROTECTION; LIVER TRANSPLANTATION; LUNG FIBROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPERFUSION INJURY; REVIEW; TREATMENT OUTCOME;

EID: 78650775101     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2010.06584.x     Document Type: Review

References (64)

1. Toledo-Pereyra LH, Simmons RL, Najarian JS. Protection of the ischemic liver by donor pretreatment before transplantation. Am. J. Surg. 1975; 129: 513.
2. Tennant R, Wiggers C. Effect of coronary occlusion on myocardial contraction. Am. J. Physiol. 1935; 112: 351-62.
3. Jennings RB, Sommers HM, Smyth GA, Flack HA, Linn H. Myocardial necrosis induced by temporary occlusion of a coronary artery in the dog. Arch. Pathol. 1960; 70: 68-78.
4. Hearse DJ, Humphrey SM, Chain EB. Ultrastructural damage associated with reoxygenation of the anoxic mycoardium. J. Mol. Cell. Cardiol. 1973; 7: 315-24.
5. Vollmar B, Menger MD. The hepatic microcirculation: mechanistic contributions and therapeutic targets in liver injury and repair. Physiol. Rev. 2009; 89: 1269-339.
6. Lautt WW, Legare DJ, Ezzatt WR. Quantitation of the hepatic arterial buffer response to graded changes in portal blood flow. Gastroenterology. 1990; 98: 1024-8.
7. Maruyabashi S, Takaneka M, Dohi K, Ezaki H, Kawasaki T. Adenine nucleotide metabolism during hepatic ischemia and subsequent blood reflow periods and its relation to organ viability. Transplantation. 1980; 30: 294-6.
8. Kawamoto S, Inoue M, Tashiro S, Morino Y, Miyauchi Y. Inhibition of ischemia and reflow-induced liver injury by an SOD derivative that circulates bound to albumin. Arch. Biochem. Biophys. 1990; 277: 160-5.
9. Yamauchi H, Baca I, Mittmann U, Geisen HP, Salzer M. Postischemic liver damage in rats: effect of some therapeutic interventions on survival rate. Tohoku J. Exp. Med. 1982; 138: 63-70.
10. Colletti L, Remick DG, Burtch GD, Kunkel SL, Strieter RM, Campbell DA Jr. Role of tumor necrosis factor-α in the pathophysiologic alterations after hepatic ischemia/reperfusion injury in the rat. J. Clin. Invest. 1990; 85: 1936.
11. Zwacka RM, Zhang Y, Halldorson J, Schlossbery H, Dudus L, Engelhardt JF. CD4+ T-lymphocytes mediate ischemia/reperfusion-induced inflammatory responses in mouse liver. J. Clin. Invest. 1997; 100: 279-89.
12. Rudiger HA, Clavien PA. Tumor necrosis factor α, but not Fas, mediates hepatocellular apoptosis in the murine ischemic liver. Gastroenterology. 2002; 122: 202-10.
13. Teoh N, dela Pena A, Farrell G. Hepatic ischemic preconditioning in mice is associated with activation of NF-κB, p38 kinase and cell cycle entry. Hepatology. 2002; 36: 94-102.
14. Teoh N, Ito Y, Field J et al. Diannexin, a novel Annexin V homodimer, provides prolonged microvascular protection against warm hepatic ischemia-reperfusion injury in mice. Gastroenterology. 2007; 133: 632-46.
15. Teoh NC, Field J, Yu J, McCuskey RS, Farrell GC. Short-term therapy with PPARα-agonist, Wy-14643 protects murine fatty liver against ischemia reperfusion injury. Hepatology. 2010; 51: 996-1006.
16. Morotto ME, Thurman RG, Lemasters JJ. Early mid-zonal cell death during low flow hypoxia in the isolated, perfused rat liver: protection by allopurinol. Hepatology. 1988; 8: 858-90.
17. Jaeschke H, Mitchell JR. Mitochondria and xanthine oxidase both generate ROS in isolated perfused rat liver after hypoxic injury. Biochem. Biophys. Res. Commun. 1989; 160: 140-7.
18. Gujral JS, Bucci TJ, Farhood A, Jaeschke H. Mechanism of cell death during warm hepatic ischemia reperfusion injury in rats: apoptosis or necrosis? Hepatology. 2001; 33: 397-405.
19. Teoh NC, Field J, Yu J, McCuskey RS, Farrell GC. Short-term therapy with PPARα-agonist, Wy-14643 protects murine fatty liver against ischemia reperfusion injury. Hepatology. 2010; 51: 996-1006.
20. 2 liberated by sources other than xanthine oxidase. Biol. Chem. 1991; 372: 35-41.
21. Samarasinghe DA, Farrell GC. The central role of sinusoidal endothelial cells in hepatic hypoxia-reperfusion injury in the rat. Hepatology. 1996; 24: 1230-7.
22. Lentsch AB, Atsushi K, Yoshidome H, McMasters KM, Edwards MJ. Inflammatory mechanisms and therapeutic strategies for warm hepatic ischemia/reperfusion injury. Hepatology. 2000; 32: 169-73.
23. Teoh NC, Farrell GC. Hepatic ischemia reperfusion injury: pathogenic mechanisms and basis for hepatoprotection. J. Gastroenterol. Hepatol. 2003; 1: 891-902.
24. Jaeschke H, Farhood A. Neutrophil and Kupffer cell-induced oxidant stress and ischemia-reperfusion injury in rat liver. Am. J. Physiol. 1991; 260: G355-62.
25. Jaeschke H. Mechanisms of neutrophil-induced liver cell injury during hepatic ischemia-reperfusion and other acute inflammatory conditions. Am. J. Physiol. Gastrointest. Liver. Physiol. 2006; 290: G1083-88.
26. Ozaki M, Deshpande SS, Angkeow P et al. Inhibition of the Rac1 GTPase protects against non-lethal ischemia/reperfusion induced necrosis and apoptosis in vivo. FASEB J. 2000; 14: 418-29.
27. Maines MD. The heme oxygenase system: update 2005. Antioxid. Redox Signal. 2005; 7: 1761-6.
28. Kapitulnik J, Maines MD. Pleiotropic functions of biliverdin reductase: cellular signalling and generation of cytoprotective and cytotoxic bilirubin. Trend Pharmacol. Sci. 2009; 30: 129-37.
29. Kravets A, Hu Z, Miralem T, Torno MD, Maines MD. Biliverdin reductase, a novel regulator for induction of activating transcription factor-2 and heme oxygenase-1. J. Biol. Chem. 2004; 279: 19916-23.
30. McCord JM. Oxygen derived free radicals in post-ischemic tissue injury. N. Engl. J. Med. 1985; 312: 159-63.
31. Amersi F, Shen XD, Anselmo D et al. Ex vivo exposure to carbon monoxide prevents hepatic ischemia/reperfusion injury through p38 MAP kinase pathway. Hepatology. 2002; 35: 815-23.
32. Katori M, Anselmo DM, Bussutil RW, Kupiec-Weglinski JW. A novel strategy against ischemia and reperfusion injury: cytoprotection with heme oxygenase system. Transpl. Immunol. 2002; 9: 227-33.
33. Coito AJ, Buelow R, Shen XD et al. Heme oxygenase-1 gene transfer inhibits inducible nitric oxide synthase expression and protects genetically fat Zucker rat livers from ischemia-reperfusion injury. Transplantation. 2002; 74: 96-102.
34. Kato H, Amersi F, Buelow R et al. Heme oxygenase-1 overexpression protects rat livers from ischemia/reperfusion injury with extended cold preservation. Am. J. Transpl. 2001; 1: 121-8.
35. Frangogiannis NG. Chemokines in ischemia and reperfusion. Thromb Haemost. 2007; 97: 738-47.
36. Okaya T, Lentsch AB. Cytokine cascades and the hepatic inflammatory response to ischemia and reperfusion. J. Invest. Surg. 2003; 16: 141-7.
37. Clarke CN, Kuboki S, Tevar A, Lentsch AB, Edwards M. CXC chemokines play a critical role in liver injury, recovery and regeneration. Am. J. Surg. 2009; 198: 415-9.
38. Mantovani A, Bonecchi R, Locati M. Tuning inflammation and immunity by chemokine sequestration decoys and more. Nat. Rev. Immunol. 2006; 6: 907-18.
39. Kuboki S, Shin T, Huber N et al. Hepatocyte signalling through CXC chemokine receptor-2 is detrimental to liver recovery after ischemia/reperfusion in mice. Hepatology. 2008; 48: 1213-23.
40. Cao X, Zhang W, Wan T et al. Molecular cloning and characterization of a novel CXC chemokine macrophage inflammatory protein-2 gamma chemoattractant for human neutrophils and dendritic cells. J. Immunol. 2000; 165: 2588-95.
41. Colletti LM, Green ME, Burdick MD, Kunkel SL, Strieter RM. Proliferative effects of CXC chemokines in rat hepatocytes in vitro and in vivo. Shock. 1998; 10: 248-57.
42. Ren X, Carpenter A, Hogaboam C, Colletti LM. Mitogenic properties of endogenous and pharmacological doses of macrophage inflammatory protein-2 after 70% partial hepatectomy in the mouse. Am. J. Pathol. 2003; 163: 563-70.
43. Teoh N, Field J, Sutton J, Farrell G. Dual role of tumor necrosis factor-α in hepatic ischemia-reperfusion injury: studies in tumor necrosis factor-α gene knockout mice. Hepatology. 2004; 39: 412-21.
44. Medzhitov R. Toll-like receptors and innate immunity. Nat. Rev. Immunol. 2001; 1: 135-45.
45. Beutler B. Inferences, questions and possibilities in Toll-like receptor signalling. Nature. 2004; 430: 257-63.
46. Kawai T, Akira S. TLR signalling. Semin. Immunol. 2007; 19: 24-32.
47. Smiley ST, King JA, Hancock WW. Fibrinogen stimulates macrophage chemokine secretion through Toll-like receptor 4. J. Immunol. 2001; 167: 2887-94.
48. Okamura Y, Watari M, Jerud ES et al. The extra domain A of fibronectin activates Toll-like receptor 4. J. Biol. Chem. 2001; 276: 10229-33.
49. Scheibner KA, Lutz MA, Boodoo S, Fenton MJ, Powell JD, Horton MR. Hyaluronan fragments act as an endogenous danger signal by engaging TLR2. J. Immunol. 2006; 177: 1272-81.
50. Matsumura T, Ito A, Takii T, Hayashi H, Onozaki K. Endotoxin and cytokine regulation of Toll-like receptor (TLR)2 and TLR4 gene expression in murine liver and hepatocytes. J. Interferon. Cytokine Res. 2000; 20: 915-21.
51. Mollen KP, Rahul J, Tsung A, Prince JM, Levy RM, Billiar TR. Emerging paradigm: toll-like receptor 4-sentinel for the detection of tissue damage. Shock. 2006; 26: 430-7.
52. Tsung A, Hoffman RA, Izuishi K et al. Hepatic ischemia/reperfusion injury involves functional TLR4 signaling in non-parenchymal cells. J. Immunol. 2005; 15: 7661-8.
53. Liu S, Salyaponge AN, Geller DA, Vodovotz Y, Billiar TR. Hepatocyte Toll-like receptor 2 expression in vivo and in vitro: role of cytokines in induction of rat TLR2 gene expression by lipopolysaccharide. Shock. 2000; 14: 361-5.
54. Zhai Y, Shen XD, O'Connell R et al. Cutting edge: TLR4 activation mediates liver ischemia-reperfusion inflammatory response via IFN regulatory factor 3-dependent MyD88-independent pathway. J. Immunol. 2005; 173: 7115-9.
55. Galloway E, Shin T, Huber N et al. Activation of hepatocytes by extracellular heat shock protein 72. Am. J. Physiol. 2008; 295: C514-20.
56. Zhai Y, Qiao B, Shen XD et al. Evidence for the pivotal role of endogenous Toll-like receptor 4 ligands in liver ischemia reperfusion injury. Transplantation. 2008; 85: 1016-22.
57. Shen XD, Ke B, Zhai Y et al. Toll-like receptor and heme oxygenase-1 signaling in hepatic ischemia reperfusion injury. Am. J. Transplant. 2005; 5: 1793-800.
58. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br. J. Cancer. 1972; 26: 239-57.
59. Malhi H, Guicciardi ME, Gores GJ. Hepatocyte death: a clear and present danger. Physiol. Rev. 2010; 90: 1165-94.
60. Tsung A, Sahai R, Tanaka H et al. The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J. Exp. Med. 2005; 201: 1135-43.
61. Ke B, Shen XD, Gao F, Bussutil RW, Kupiec-Weglinski JW. Interleukin 13 gene transfer in liver ischemia reperfusion injury: role of Stat6 and TLR4 pathways in cytoprotection. Hum. Gene Ther. 2004; 15: 691-8.
62. Zeng S, Feirt N, Goldstein M et al. Blockade of receptor for advanced glycation end product (RAGE) attenuates ischemia and reperfusion injury to the liver in mice. Hepatology. 2004; 39: 422-32.
63. Zeng S, Dun H, Ippagunta N et al. Receptor for advanced glycation end product (RAGE)-dependent modulation of early growth response-1 in hepatic ischemia reperfusion injury. J. Hepatol. 2009; 50: 929-36.
64. Xu Y, Toure F, Qu W et al. Advanced glycation end product (AGE)-receptor for AGE ( (RAGE) signaling and upregulation of Egr-1 in hypoxic macrophages. J. Biol. Chem. 2010; 285: 23233-40.